Join Now

The voice of utah’s life sciences community

BioUtah is the common voice and flag bearer for Utah’s life sciences industry comprised of medical devices, pharmaceutical, diagnostics, and biotechnology. Together we form an ecosystem that fosters collaboration, promotes innovation and delivers technology that saves lives.

Learn More

Medical Device

Pharmaceuticals

Diagnostics / Laboratory

Biotechnology

Icons made by Freepik from www.flaticon.com is licensed by CC 3.0 BY

2024 Utah Life Sciences Award Recipients

Lifetime Achievement
Dr. Wm. Dean Wallace

Innovation Impact
Blackrock Neurotech

Entrepreneur of the Year
Jay Muse

Executive of the Year
Bradford Brown

Friend of Industry
Vic Hockett

Utah Life Sciences by the Numbers

Kem C. Gardner Report Findings Nov. 2023

Utah is #3 in the nation for life sciences growth.

Life sciences is a $21.6 billion industry in Utah.

Source: Pace, L. and Brandley, A. (2023), Economic Impacts of Utah’s Life Sciences and Health Care Innovation Industry: Utah’s Life Sciences and Health Care Innovation Industry Creates Substantial Economic Impacts Across the State, Kem C. Gardner Policy Institute, University of Utah.

BioUtah News

December 5, 2024
BioUtah News
PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinson’s Trial at PSG Annual Meeting

Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt Lake City, Utah — December 5, 2024 — PhotoPharmics, a pioneer in non-invasive phototherapy for neurological disorders, today announced it will present a poster titled “An Entirely Remote, Home-based Phase 3 Clinical Trial of a Specialized Light Therapy Device for Parkinson’s Disease […]

December 5, 2024
BioUtah News
Fluidx Medical Begins Multinational Trial of GPX Embolic Device

November 27, 2024—Fluidx Medical Technology, Inc. announced that the first patient has been treated in the prospective, multinational, clinical trial of the company’s GPX embolic device. The device was successfully used in a portal vein embolization procedure in preparation for hepatic resection. According to the company, the safety and effectiveness trial includes leading medical centers […]

December 5, 2024
BioUtah News
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson’s disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that […]

December 5, 2024
BioUtah News
Canary Speech Named to the 2024 CB Insights’ List of the 50 Most Innovative Digital Health Startups

Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe.

December 5, 2024
BioUtah News
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized

November 27, 2024
BioUtah News
Fluidx Medical Announces First Tumor Patient Treated in Prospective, Multinational Trial

Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses.

November 26, 2024
BioUtah News
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA

November 26, 2024
BioUtah News
Merit Medical’s WRAPSODY WAVE Trial Exceeds Performance Goals for Arteriovenous Graft (AVG) Patients

WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial

From Here to There

See how BioUtah, the only trade association dedicated solely to Utah’s Life Sciences industry, can help your business grow.


Networking

Advocacy

Investment

Workforce Development

BioUtah is Powered by

Legacy Sponsors

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Bronze Sponsors